ANTIGENICS ANNOUNCES ONCOPHAGE STUDY FINDINGS

A A

Antigenics has announced updated findings from a Phase III clinical trial of the company's investigational cancer vaccine Oncophage (vitespen; formerly HSPPC-96) in metastatic melanoma.

In the study, patients who received at least 10 doses of vaccine experienced an extension in median survival of 29 percent compare dwith those who received physician's choice. In a subset analysis, Oncophage was associated with a potentially clinically relevant benefit compared with physician's choice for patients with stages IV M1a and M1b melanoma,if at least 10 doses of vaccine were administered.